Join us.


Senior Chemical Biologist

With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.


The Role

The Early Discovery Chemistry Team enables the validation of our AI-derived target predictions and facilitates their entry into the BAI drug discovery portfolio. Collaborating with teams across the organisation, we support the development of therapeutic strategies, undertake target tractability assessments and target deconvolution experiments, and build state-of-the-art AI-augmented products to improve the process. We are looking for a highly innovative, engaging and proactive chemical biologist to join our multidisciplinary team. This is a non-lab-based role in our London headquarters and involves close collaboration with our Cambridge lab-based scientists.

Primary Responsibilities

  • Lead the target deconvolution efforts across our target identification portfolio, including the design and delivery of relevant chemistry and biology experiments through internal and external collaborators. This will involve a variety of experiments tailored to the target and cellular context, ranging from cell-free target panels, to lysate pull-downs and thermal proteomic profiling.
  • Responsible for the maintenance and development of the BenevolentAI chemogenomic library, including management of compound synthesis.
  • Undertake target tractability assessments to support target validation and discovery portfolio investment decisions.
  • Identify and implement emerging technologies to strengthen our capabilities in target deconvolution and hit identification.
  • Contribute towards the development of our target assessment products, including our automated structural bioinformatics platform to support target deconvolution.
  • Regularly present your research and recommendations for target validation and tractability to the drug discovery senior leadership team.

We are looking for someone with

  • A PhD or equivalent experience in chemical biology.
  • Lab-based experience in both synthetic chemistry and cell biology.
  • Expertise in modern chemical biology techniques for the functionalisation of chemical tools for target engagement and deconvolution.
  • Self-motivated, proactive, innovative, with the ability to devise and implement solutions in a timely manner.
  • Excellent communication skills with a desire to work in multidisciplinary teams.
Nice to haves:
  • Experience working in the drug discovery industry.
  • Hands-on experience in using biological assays for target engagement and off-target profiling.
  • Knowledge of cellular extract thermal shift assays, including the use of chemoproteomic profiling.
  • Experience in the use of Western Blotting techniques.
  • An understanding of the application of structural bioinformatics and chemoinformatics for target deconvolution.

We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey.  If that sounds like a fit for you, hit the apply button and join us.

About us

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Want to do a little more research before you apply?

Head over to our Glassdoor page to learn about our benefits, culture and to find out what our team thinks about life at Benevolent. You can also find out more about us on LinkedIn and Twitter.

Important Note

Our team will only contact you from the domain If you receive a suspicious contact request, please email Thank you.